Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Marketing Strategies for Participating Hospitals to Be Important for Drug Makers to Effectively Use MID-NET: PMDA Official
May 11, 2017
- LDP Confab Sees Japan Execs’ Chorus for Drug Price Maintenance during Patent Term
May 10, 2017
- Japan, US Ink Memorandum of Cooperation on Health
May 9, 2017
- Health Minister Shiozaki Stresses Importance of US-Japan Alliance in Healthcare
May 9, 2017
- Japan and India to Share Common View on Global Clinical Trials
May 9, 2017
- “Specified Clinical Research” Data with High Integrity Could Be Used for Drug Review: MHLW Councilor
May 8, 2017
- Experts Support Revision of Rules to Promote Concurrent Administration of Multiple Vaccines: MHLW Vaccine Panel
May 8, 2017
- MHLW Study Group Drafts “Items to Consider” to Promote Development of Nucleic Acid Drugs
May 2, 2017
- MHLW Poised to Create Standards for Cancer Treatment in the Elderly
May 1, 2017
- 2017 Economic and Fiscal Policy Guidelines Likely to Be Tinged with MOF Color
April 28, 2017
- MHLW to Draw Up Guidelines on Use of MID-NET in Summer
April 28, 2017
- LDP Health Panel Holds Drug Pricing Hearing with Doctor, Pharmacist Groups
April 28, 2017
- Ad-Hoc Generic Prices for “Off-Year” Revisions Acceptable: Chuikyo Bill Payer Reps
April 27, 2017
- JMA’s Nakagawa Says MHLW Should Fuel Generic Industry Realignment: Chuikyo
April 27, 2017
- Savings from Generic Use Increase Sharply from FY2013 through FY2015: MHLW Estimate
April 27, 2017
- New LDP Lawmaker Group on Generics to Draw Up Proposal for 2017 Fiscal Blueprint
April 26, 2017
- Non-Partisan Lawmaker Group on Cooperation with WHO Set Up, Eyeing Asia Pacific Region Congress in Japan this Summer
April 26, 2017
- Me-Too Drugs in Jeopardy? CEFP Working Group Pushes Rigid Drug Selection for Innovation Premium
April 26, 2017
- LDP Health Panel to Compile Resolution on Drug Pricing
April 25, 2017
- Drug Pricing Is Internal Affairs Not Subject to Bilateral Talks: Minister
April 25, 2017
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…